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Absolute, Not Relative, Changes Are
Important When Interpreting Trial Data
Tsutamoto et al. (1) have recently reported on the beneficial effects
of spironolactone on plasma neurohormones and echocardio-
graphically derived left ventricular (LV) volume and mass indices
in patients with nonischemic congestive heart failure. Though
spironolactone is known to reduce morbidity and mortality in
severe heart failure, many of the mechanisms underlying these
effects have yet to be fully elucidated (2). Because aldosterone has
direct myocardial actions that may play an important role in LV
remodeling, it is particularly relevant to investigate the effects of
spironolactone on this process.
However, several points need careful consideration when inter-
preting the data presented by Tsutamoto et al. (1). First, the
investigators state that no significant differences existed between
the placebo- and spironolactone-treated groups at baseline. How-
ever, this seems somewhat surprising considering that the mean
baseline plasma-active renin concentration was 234 pg/ml in the
placebo group but only 93 pg/ml in the spironolactone group.
Furthermore, it appears that LV ejection fraction (LVEF) was
greater and both LV end diastolic volume and mass were lower in
the placebo group. Although these differences in echocardio-
graphic parameters did not reach significance, they have an
important bearing when interpreting the results after four months
of active therapy. The researchers concluded that spironolactone
treatment resulted in an improvement in indices of LV remodel-
ing, which was based upon a significant difference in changes of
echocardiographic parameters between the two groups at four
months. However, when determining the clinical relevance of a
novel therapy in any placebo-controlled study it is imperative to
compare the absolute means between the two groups at follow-up.
In our opinion, the investigators should have performed an
unpaired t test between the groups after four months of treatment.
As this has not been mentioned in the report by Tsutamoto et al.
(1), should we assume that these differences did not reach
statistical significance? This possibility is supported by the absolute
values given in the researchers Table 2 (1). For example, although
spironolactone therapy resulted in an increase in LVEF of 2.8%
(p  0.05), the absolute value of 35% after four months of
treatment was similar to that in the placebo group (baseline,
36.6%; four months, 36.3%). This demonstrates the potential
pitfalls of preenting relative changes as opposed to absolute values
in assessing the clinical benefits of a therapeutic agent.
One of the reasons that Tsutamoto et al. (1) were unable to
demonstrate a significant improvement in indices of LV remod-
eling (in terms of absolute values) may relate to the fact that the
measurements were made using echocardiography. This technique
is known to have poor reproducibility when applied to subjects
with impaired LV function. In contrast, cardiac magnetic reso-
nance imaging provides highly reproducible assessments of cardiac
volumes, function and mass in patients with heart failure (3). It is
especially important to use a technique with high reproducibility
when attempting to demonstrate significant differences using
relatively small numbers of participants, as was the case in the
study by Tsutamoto et al. (1).
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REPLY
We appreciate the important remarks by Kalra et al. on our article
(1). We compared left ventricular (LV) volume and mass, as well
as plasma levels of atrial natriuretic peptide (ANP), brain natri-
uretic peptide (BNP) and procollagen type III aminoterminal
peptide (PIIINP), before and after treatment with spironolactone
or placebo. The LV volume and mass were significantly decreased
in the spironolactone group, but not in the placebo group. Plasma
levels of ANP, BNP and PIIINP were significantly decreased by
spironolactone, but did not change in the placebo group. A
significant positive correlation existed between the changes of
PIIINP and changes of the LV mass index with spironolactone
treatment. These findings indicate that four months of spirono-
lactone treatment improved LV volume and mass and decreased
the plasma level of BNP in nonischemic patients with congestive
heart failure (CHF).
In our study (1), to the evaluation of LV mass and LV function
in nonischemic CHF patients, we performed M-mode echocardi-
ography with two-dimensional (2-D) monitoring using a Sono-
layer phased-array sector scanner in a blinded fashion before and
after four months of treatment with spironolactone or placebo.
The LV volumes were calculated using Teichholtz’s formula, and
the LV ejection fraction was determined. The LV mass was
calculated using a method reported previously (2). An earlier study
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(3) reported a significant close correlation between the 2-D
echocardiographic LV mass and the necropsy LV mass, and we
followed the recommendation of the Committee on M-Mode
Standardization of the American Society of Echocardiography (2).
We believe that M-mode echocardiography with 2-D monitoring
in a blinded fashion was sufficient to evaluate LV mass and LV
function, especially in nonischemic CHF patients who were the
subjects of this study and who had diffuse LV hypokinesis and no
focal hypertrophy by 2-D echocardiography. Actually, we have
reported that there was a close correlation between LV mass by
echocardiography and LV mass by magnetic resonance imaging in
patients with essential hypertension (4).
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Increased von Willebrand Factor
in the Endocardium as a Local
Predisposing Factor for Thrombogenesis
in Overloaded Human Atrial Appendage
We read with great interest the article by Fukuchi et al. (1),
describing immunohistochemical evidence of increased expression
of von Willebrand factor (vWF) in the endocardium of “overload-
ed” human atrial appendages, as a possible mechanism of intra-
atrial thrombogenesis. They describe an increase in atrial endocar-
dial vWF expression in patients with mitral valve disease (MVD)
and heart failure, but state that the level of vWF expression is
unaffected by the presence of atrial fibrillation (AF). Although we
welcome the work as an advancement in our understanding of
intra-atrial thrombogenesis, we respectfully suggest that Fukuchi
et al. (1) may have understated the potential importance of AF and
vWF expression in the endocardium of the left atrial appendage
(LAA).
Fukuchi et al. (1) did not show a difference in vWF expression
by direct comparison of the LAA of MVD and non-MVD (that is,
heart failure) patients. In fact, only heart failure patients (n  4)
showed a significant increase in right atrial appendage (RAA)
vWF expression compared with other cardiac patients, but all of
the heart failure specimens were obtained postmortem, whereas all
other cardiac patient specimens were obtained during cardiac
surgery. Perhaps the main finding that can be truly relied upon was
the detection of a significant difference between LAA and RAA
levels of vWF expression in patients with MVD, with greater levels
of vWF in the LAA endocardium compared to the RAA. This
finding, coupled with the reported correlation between increased
levels of vWF expression and the degree of observed platelet
adhesion, could suggest a mechanism for left atrial (LA) thrombus
development, which is associated with mitral stenosis.
Unfortunately, Fukuchi et al. (1) do not clarify the proportion of
MVD patients with mitral stenosis or mitral incompetence, as
mitral incompetence is believed to be associated with a reduction in
risk of intra-atrial thrombogenesis. In a study using scanning
electron microscopy (SEM), we recently reported evidence of more
advanced endocardial changes in the LAA compared with the
RAA in MVD patients, and among specimens from patients with
mitral stenosis when compared to those with mitral incompetence
(2). Furthermore, increasing plasma levels of vWF, an established
plasma marker of endothelial damage/dysfunction, were seen to
correlate with more advanced SEM endocardial changes. There
was also a nonsignificant trend toward increased endocardial
changes in MVD patients with AF compared to sinus rhythm.
Because AF was present in 12 of the 15 MVD patients studied by
Fukuchi et al. (1), the possibility arises that the presence of AF
itself (or, at least, in combination with mitral stenosis) led to the
increase in LAA expression of vWF in their study.
Fukuchi et al. (1) state that the presence of AF appeared not to
influence the LAA expression of vWF, but this is based on only
four specimens obtained from patients in sinus rhythm, of which at
least one was from a postmortem specimen without MVD. In
contrast, all 12 LAA specimens from the AF group were taken
from live patients with MVD during a Maze procedure; thus, the
comparison may be underpowered and poorly standardized. Sec-
ond, although the comparison of RAA vWF levels was more
appropriately powered, standardization between the two groups
was again poor, with 12 out of a total of 16 AF patients studied
having MVD, compared with only 3 out of 27 sinus rhythm
patients. Furthermore, because the LAA is the main site of
thrombogenesis in patients with AF, the lack of observed RAA
changes may be of limited clinical significance.
Atrial fibrillation, with or without the additional presence of
MVD, has been shown to be associated with increased levels of
circulating plasma vWF, as well as other markers of thrombogen-
esis and platelet activation (3). We have demonstrated that
peripheral levels of vWF have been shown to be similar to
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